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Abstract
Background: Neurotrophic factors have been shown to possess strong neuroprotective and neurorestaurative properties in
Parkinson’s disease patients. However the issues to control their delivery into the interest areas of the brain and their
surgical administration linked to their unability to cross the blood brain barrier are many drawbacks responsible of
undesirable side effects limiting their clinical use. A strategy implying the use of neurotrophic small molecules could provide
an interesting alternative avoiding neurotrophin administration and side effects. In an attempt to develop drugs mimicking
neurotrophic factors, we have designed and synthesized low molecular weight molecules that exhibit neuroprotective and
neuritogenic potential for dopaminergic neurons.
Principal Findings: A cell-based screening of an in-house quinoline-derived compound collection led to the
characterization of compounds exhibiting both activities in the nanomolar range on mesencephalic dopaminergic neurons
in spontaneous or 1-methyl-4-phenylpyridinium (MPP
+)-induced neurodegeneration. This study provides evidence that
rescued neurons possess a functional dopamine transporter and underlines the involvement of the extracellular signal-
regulated kinase 1/2 signaling pathway in these processes.
Conclusion: Cell-based screening led to the discovery of a potent neurotrophic compound possessing expected physico-
chemical properties for blood brain barrier penetration as a serious candidate for therapeutic use in Parkinson disease.
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Introduction
Loss of dopaminergic (DA) neurons within the substantia nigra
pars compacta (SNpc) is a consistent feature of Parkinson’s
disease (PD). This is mainly clinically characterized by motor
impairments [1]. Except for some cases linked to specific gene
defects (,10%), PD is a sporadic combination of unknown
factors [2]. Mitochondrial dysfunction, oxidative stress, and
proteasome failure are among the several hypotheses put forward
to explain the molecular basis of neuronal damage [3,4]. The
symptoms of PD can be improved by drugs that replace
neurotransmitters, but these treatments are unable to slow down
the disease progression and often induce undesirable side effects
[5]. New therapies are required to preserve DA neurons and
stimulate their DA activity and to limit or halt the progression of
the disease [6]. Several neurotrophins implicated in the
development and maintenance of different neuronal populations
have been shown to provide protection against cell death in in
vitro and in vivo models of PD through diverse signaling pathways
including activation of phosphatidylinositol–3-kinase (PI3-ki-
nase)/Akt, ras-dependent mitogen-activated protein kinase
(MAPK), and phospholipase C (PLC) [7]. These signaling
cascades lead to the prevention of apoptotic cell death, promotion
of cellular differentiation and neuritogenesis. Glial-cell derived
neurotrophic factor (GDNF) has been proposed as a therapeutic
agent to delay the development of PD [8]. Despite the
therapeutic potential of GDNF, clinical trials have been
disappointing [9], probably due to inherent drawbacks associated
with the use of polypeptides applied as drugs [10], including
pleiotropic effects, short half-life and inability to cross the blood-
brain barrier (BBB), thus imposing repeated transcranial
injections, with dramatic side effects. To obviate these issues,
substantial efforts have been made to design non-peptidic small
molecules with neurotrophin-like activities.
Lembehyne A (LBA), a natural polyacetylene isolated from
Haliclona sp. marine sponges, was previously described for its
neurotrophic properties for the mouse neuroblastoma cell line
Neuro2A [11]. Structure–activity relationship studies determined
the minimal structure required for activity [12]. Inspired by this
natural biologically active product, we designed and synthesized
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linking the neuritogenic part of LBA to a putative neuropro-
tective quinoline ring largely described for its high biological
potential [13–17] with the aim of producing chemicals
possessing a neurotrophin-like activity. Herein, we report the
design, synthesis and cell-based screening of small molecules
exhibiting both neuroprotective and neuritogenic activities on
rat mesencephalic DA neurons against spontaneous [18] or
MPP
+-induced [19] degeneration. Preliminary studies of the
mechanism of action revealed that the most active compound
exerts its activity through ERK1/2 signaling pathway activation,
especially on DA neurons.
Results
Chemical syntheses
Terminal alkynols 3a–c are the first intermediates of our
multistep synthesis leading to the lateral chain of our products.
First, propargylic alcohol 1 was coupled to bromoalkanes through
a previously described cross-coupling reaction [20] involving an
iron catalyst and lithium amide to give compounds 2a–c.I na
second step, a zipper reaction [21] led to terminal alkynols 3a–c.
This was followed by a Sonogashira cross-coupling reaction [22]
between 2-chloroquinoline or 3-bromoquinoline, both commer-
cially available, and terminal alkynols 3a–c giving alcohol
intermediates 4a–f. Best yields were obtained by using
PdCl2(PPh3)2 and CuI as catalysts and Et3N as base. Alcohol
intermediates 4a–f were then oxidized into the corresponding
aldehydes through a Swern oxidation [23] to give compounds 5a–
f. This oxidation was followed by a final coupling reaction
between aldehydes 5a–f and commercially available trimethylsi-
lylacetylene after metallation with n-butyllithium to give a silylated
intermediate that was immediately deprotected with tetrabuty-
lammonium fluoride leading to compounds 6a–f. In order to
study the influence of the benzylic triple bond on the biological
activity, another series was synthesized from compounds 4a–f
after catalytic hydrogenation of the triple bond, leading to
saturated alcohol intermediates 7a–f. Compounds 7a–f were
then oxidized into the corresponding aldehydes 8a–f and coupled
to trimethylsilylacetylene before deprotection through the same
steps as for compounds 4a–f. With the aim of studying the
influence of terminal propargylic alcohol on the biological activity,
Figure 1. Syntheses of quinoline-derived compounds. Reagents and conditions were as follows. (A) (a) Fe(NO3)2.9H2O (cat), Li (3 equiv), NH3,
240uC to rt, 6 h; (b) NaH (6.3 equiv), NH2(CH2)3NH2,7 0 uC, overnight (4a) bromooctane (1 equiv) (4b) bromodecane (1 equiv) (4c) bromododecane (1
equiv); (c) PdCl2(PPh3)2 (0.05 equiv), CuI (0.1 equiv), Et3N (5 equiv), THF, reflux, 3 h. (4a–c) 2-chloroquinoline (1 equiv) (4d–f) 3-bromoquinoline (1
equiv); (d) (i) DMSO (5.8 equiv), (ClCO)2 (2.2 equiv), CH2Cl2, 250uC, 15 min then 2 h. (ii) Et3N (10 equiv), 250uC to rt; (e) (i) HC;C-TMS (1 equiv), n-BuLi
(1.2 equiv), 278uC, 1 h (ii) TBAF (1.06 equiv), THF, rt, 10 min. (f) BrMg- CH=CH2 (1.2 equiv), THF, 278uC, 2 h. (g) BrMg-cyclopropyl (1.2 equiv), THF,
278uC, 2 h. (B) (h) H2, Pd/C (20% w:w), EtOHabs, rt, overnight.
doi:10.1371/journal.pone.0006215.g001
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aldehyde 5c by adding vinyl or cyclopropyl magnesium bromide
to give the corresponding compounds 6g and 6h. Compound
quinoline-free 9g was prepared in the same way from the
corresponding aldehyde 8g of commercially available alcohol 7g.
The different steps are presented in Fig. 1. Spectroscopic data are
available in the Supporting Information S1 (see Supplementary
Information - Spectroscopic analysis).
Screening for both Neuroprotective and Neuritogenic
Activities on DA Neurons
Synthesized compounds were then assessed for their ability to
protect DA neurons from degeneration and activate neuritogen-
esis. The screening was performed in primary mesencephalic
cultures displaying a progressive degeneration of DA neurons [18]
(see Supplementary Information - Mesencephalic cultures). Cultures were
maintained for 8 days in the presence or absence of the different
tested compounds, and then tyrosine hydroxylase (TH) was
immunolabeled to allow the analysis of DA neurons (see
Supplementary Information - Immunocytochemistry). Neuroprotection
was assessed by TH immunopositive (TH
+) neuron counting (see
Supplementary Information - Survival quantification). Neuritogenesis,
expressed as total neurite length per DA neuron, was quantified
using image analysis software on at least 100 neurons randomly
photographed per condition (see Supplementary Information -
Neuritogenesis quantification). Results are given in Table 1 and give
rise to several interesting observations. First, compounds such as
6a–c, 9a–c, 4b and 6g,h exhibited both protective and
neuritogenic activities in the nanomolar range. Second, a strong
selectivity for both activities was observed between the 2- and 3-
substituted quinolines (6a–c vs. 6d–f,P ,0.001, Table 1), as
represented in Fig. 2B–C. Third, the activities were significantly
increased with the length of the lateral chain (6a vs. 6b vs. 6c,
P,0.05, Table 1) and the best dual activities were observed for
compound 6c (Table 1, Fig. 2A–C). Furthermore, saturation of
the intrachain triple bond significantly decreases the activities
(6a–c vs. 9a–c,P ,0.001, Table 1). Fourth, the removal (6b vs.
4b) or replacement (6c vs. 6g, 6c vs. 6h) of the terminal triple
bond significantly decreases (P,0.001, Table 1) the protective
effect but not the neuritogenic effect. The dose–effect relationship
(data not shown) revealed that maximal effect was observed at a
10 nM concentration for compounds 6g and 6h. Finally, removal
of the quinoline ring canceled out the protective effect without
changing neuritogenesis (6c vs. 9g,P ,0.001, Table 1). A two-
dimensional diagram showing the distribution of screened-
compounds into four groups for both activities is shown in
Fig. 2A. These data demonstrated a crucial role of the
substitution position of the quinoline ring in this series of
compounds and the contribution of both ring and terminal triple
bond to the protective effect whereas the neuritogenic activity
seemed to be mainly due to the presence of the lateral
hydroxylated chain. Further investigations were carried out with
compound 6c which showed the best activity for both
neuroprotection and neuritogenesis.
Table 1. Neuroprotective and neuritogenic activities of LBA-derived compounds on mesencephalic DA neurons.
R
1-Fg-(CH2)3-(CH2)n-(CH2)4-CH(OH)R
2 % relative to control6SEM
Compound
a Functional group (Fg) R
1 R
2 nT H
+ neurons
b Length/TH
+ neuron
c
Control 10062.7 10062.9
dbc-AMP 149.963.6 333.168.7
6a C;C 2-quinolinyl C;CH 1 127.267.4 150.667.6
6b C;C 2-quinolinyl C;CH 3 141.464.6 155.266.3
6c C;C 2-quinolinyl C;CH 5 154.564.1 186.067.7
6d C;C 3-quinolinyl C;CH 1 86.869.5 51.363.7
6e C;C 3-quinolinyl C;CH 3 89.662.8 55.262.0
6f C;C 3-quinolinyl C;CH 5 98.266.3 78.562.2
9a CH2-CH2 2-quinolinyl C;CH 1 115.863.9 126.5610.8
9b CH2-CH2 2-quinolinyl C;CH 3 129.665.3 122.368.7
9c CH2-CH2 2-quinolinyl C;CH 5 142.662.6 128.861.0
9d CH2-CH2 3-quinolinyl C;CH 1 NR
d NR
d
9e CH2-CH2 3-quinolinyl C;CH 3 NR
d NR
d
9f CH2-CH2 3-quinolinyl C;CH 5 117.666.1 95.862.9
4b C;C 2-quinolinyl H 3 121.463.1 157.9613.9
4e C;C 3-quinolinyl H 3 103.964.2 114.3610.7
6g C;C 2-quinolinyl v
f 5 135.562.7
e 160.6611.4
e
6h C;C 2-quinolinyl CH=CH2 5 139.164.2
e 163.5614.2
e
9g CH2-CH2 HC ;CH 5 95.865.9 163.8611.8
aCompounds used at 100 nM concentration.
bNumber of TH
+ neurons per well as a percentage of untreated cultures expressed as the mean6SEM of at least three independent experiments performed in triplicate.
cNeurite length per neuron as a percentage of untreated neurons measured on at least 100 neurons per condition using an image analyser (Neurite Outgrowth, Explora
Nova, France) and expressed as the mean6SEM of three independent experiments performed in triplicate.
dNon-determined.
eRelated values obtained at 10 nM because of a weak toxicity observed at 100 nM.
fv=cyclopropyl. Statistical analysis was performed by one-way ANOVA followed by Bonferroni’s post hoc test (P,0.001, reported in text).
doi:10.1371/journal.pone.0006215.t001
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on DA Neurons
DA neurons represent only a few percent among the total
neuronal population in ventral mesencephalon culture, which is
mainly constituted by GABA (gamma-amino-n-butyric acid)-ergic
neurons [24]. GABA neurons are not affected under these
conditions so their number, assessed by counting microtubule-
associated protein 2 (MAP2) immunolabeled-neurons, is only
representative of total neuronal viability (Fig. 3A) [25]. To explore
the phenotypic specificity of compound 6c, uptakes of [7,8-
3H]-
DA ([
3H]-DA) and 4-Amino-n-[2,3-
3H]-butyric acid ([
3H]-GABA)
were measured under the same conditions (see Supplementary
Information – Uptake of neurotransmitters). Uptake measurements were
carried out at DIV12 to allow neuronal maturation. Fig. 3B
provides evidence that DA uptake was increased in compound 6c-
treated cultures in a dose-dependent manner, while the latter has
no influence on [
3H]-GABA uptake. These data suggest that
compound 6c-induced neurotrophic activity is specific to DA
neurons under these conditions.
Protective Effect of Compound 6c Against Neurotoxin 1-
methyl-4-phenylpyridinium (MPP
+) Toxicity
Since toxins could be involved in PD onset [26–29], there is
growing interest finding the search for compounds able to protect
DA neurons from toxin-induced death. To examine more closely
the protective potential of compound 6c, MPP
+ was added to
mesencephalic cultures (see Supplementary Information – MPP
+
intoxication). This inhibitor of mitochondrial complex I is
specifically toxic for DA neurons in a dose-dependent manner
[19]. In the present study, addition of 2, 3, or 4 mM of MPP
+ to
mesencephalic cultures between DIV5 and DIV7 decreased the
number of TH
+ neurons and induced neurite degeneration, as
shown in Fig. 4A–B. Addition of compound 6c significantly
increased the survival of TH
+ neurons at 10 nM on 2 mM MPP
+-
treated cultures (P,0.05). The effect decreased with MPP
+
concentration but was still significant at 1 mMi n4mM MPP
+-
treated cultures (P,0.05). In addition to rescuing TH
+ neurons
from MPP
+-induced toxicity, compound 6c protected neurites
from MPP
+-induced degeneration, as illustrated in Fig. 4B.
Compound 6c-induced Neurotrophic Effect is
Independent of Glial Proliferation
In vitro neuroprotective processes were previously linked to an
inhibition or an activation of glial proliferation [30,31]. To explore
the influence of compound 6c on proliferating cells in mesence-
phalic cultures, [methyl-
3H]-thymidine, a marker of DNA
synthesis used to label proliferating cells, was incorporated in the
cultures for 18 hours at 37uC then washed before fixation at DIV8,
as previously described [32]. An autoradiographic revelation
allowed spotting and counting of radioactive nuclei. As outlined in
Fig. 5, no effect of compound 6c was observed on proliferating
cells under these conditions in comparison with the mitogenic
Figure 2. Screening for both neuroprotective and neuritogenic activity on DA neurons. (A) Two-dimensional representation of Table 1
showing four main groups of compounds exhibiting or not both neuroprotective and neuritogenic activity in different ratios. (B) The substitution
position of the lateral chain is crucial for both activities (6c vs. 6f). 2-substituted compounds induced an increase in both TH neuron survival and
neuritogenesis in a dose-dependent manner, while 3-substituted compounds inhibited both activities. Dbc-AMP at 200 mM was used as a positive
control. Values are normalized to the non-treated control (CTL) and represent the average of at least three assays realized in triplicate and are
expressed as mean6SEM. *P,0.001. Statistical analysis was performed by one-way ANOVA followed by Bonferroni’s post hoc test. (C) Compound 6c
(b) increased the number and the length of DA neuron processes compared to non-treated cultures (a). In contrast, neuritogenesis of DA neurons in
compound 6f-treated cultures (c) was slowed down, showing the crucial role of the substitution position on the combined activity. (b) and (c)
represent (tyrosine hydroxylase) TH immunolabeled neurons in cultures treated with 100 nM of compounds 6c and 6f. A dose-dependent
neuritogenic effect was also observed for compound 6c (data not shown), while compound 6f was still inactive at higher concentrations (data not
shown). Dbc-AMP at 200 mM (d) was used as a positive control. Images were acquired with an inverted fluorescent microscope coupled to a digital
camera.
doi:10.1371/journal.pone.0006215.g002
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arabinoside-C (ARA-C). This result suggests that the compound
6c-induced neurotrophic effect is independent of glial cell
proliferation.
Involvement of Extracellular Signal-regulated Kinase
(ERK1/2) Activation in Compound 6c-induced
Neurotrophic Effect
Activation of ERK1/2 phosphorylation has been reported to
contribute to neuronal cell survival in models of neurotoxicity [33–
35]. To further investigate the molecular signaling pathway
involved in the activity induced by compound 6c, we evaluated
the effect of compound 6c treatment upon MAPK and ERK1/2
activation (see Supplementary Information – Western Immunoblotting of
ERK1/2). First and foremost, we proved that compound 6c is a
potent neurotrophic factor for DA neurons and further hypothe-
sized that regulationofERK1/2 phosphorylationmightbe involved
in the compound 6c-induced neurotrophic effect. First, PD98059,
an inhibitor of MAPK kinase (MEK) [32], abolished the protective
(Fig. 6A) and neuritogenic (Fig. 6B) effects of compound 6c.
Furthermore, stimulation of mesencephalic cultures with 100 or
1000 nM of compound 6c resulted in an increase in ERK1/2
phosphorylation, as shown in Fig. 6C. In addition, we observed that
compound 6c treatment increased phospho-ERK1/2 immunore-
activity in DA neurons (Fig. 6D). Our results suggest that activation
of the ERK1/2 pathway is an essential mechanism involved in
compound 6c-induced neurotrophic activity on DA neurons.
Discussion
Since currently marketed CNS drugs are unable to provide a
decrease in degeneration in PD [36], neuroprotective and
neurorestorative approaches are ongoing [37]. In recent years,
great success has been achieved on the use of neutrophins as
therapeutic agents. Their potent efficacy to prevent DA neurons
from death and restore DA activity was first demonstrated in cell-
based and animal models [38,39], but the following phase II
clinical assays, though preliminarily encouraging, ultimately failed
[40]. Given their polypeptidic structure, their large molecular
weight, short half-life and inability to cross the BBB mean that
surgical administration is required, with potentially severe side
effects. This therefore limits their therapeutic use. Non-peptidic
small molecules with neurotrophic properties may provide a mean
to avoid these drawbacks [41].
We report here the discovery of quinoline-derived compounds
as neurotrophin mimetics. These compounds behave as neuro-
trophins with nanomolar activity unprecedented for low molecular
weight neurotrophic compounds. Structure–activity relationship
analysis revealed not only that the presence of the quinoline ring is
crucial for dual activity but also that the substitution position plays
a decisive role in the neurotrophic effect. The presence of
intrachain triple bond increases the activity which is in contrast
with previous reports showing that unsaturations have no influence
on the LBA-induced differentiation [12]. These findings suggest
that the electronic delocalization between the benzylic donor
moiety and the heterocyclic nitrogen in 2-substituted quinolines is
strongly implicated in the effect. Furthermore, the removal or
replacement of the terminal triple bond decreased the protective
effect, which correlates with studies related to rasagiline [42,43]
demonstrating the potential of the propargylic group in rasagiline-
induced neuroprotection. In these cases, the neuritogenic effect is
not affected, which is in accordance with previous reports of
compounds possessing lateral hydroxylated long chain as differ-
entiation inducers [44]. This provides evidence that the introduc-
tion of the triple bond to the hydroxylated long chain of neuronal
differentiation inducers led to compounds combining dual
protective and neuritogenic activities in the nanomolar range.
All our results suggest that both the ring and the terminal
propargyl alcohol contribute to the protective effect, while the
neuritogenic activity seems to be mainly due to the presence of the
lateral hydroxylated chain. However, this is complicated by the
fact that the length of the lateral chain and the presence of the
benzylic triple bond also have an influence on the protective effect.
In addition, our study demonstrates that the compound 6c-
induced neurotrophic effect on DA neurons is mediated via the
activation of the ERK1/2 signaling pathway. This result is
particularly interesting since the MAPK signaling cascade is
involved in neurotrophin-induced neuronal survival and neurito-
Figure 3. Specificity of compound 6c-induced neurotrophic
effect on DA neurons. (A) The number of DA and total neurons in 6c-
treated cultures was evaluated by counting of TH and MAP-2
immunolabeled neurons. The treatment with compound 6c has no
effect on the viability of MAP-2
+ neurons, while the number of TH
+
neurons wa significantly increased in a dose-dependent manner. (B)
[
3H]-DA and [
3H]-GABA uptake in 6c-treated cultures. Compound 6c
had no effect on [
3H]-GABA uptake, while [
3H]-DA uptake was
significantly increased in a dose-dependent manner showing the
specificity of the effect of compound 6c on DA neurons in these
conditions. Values are normalized to the untreated control (CTL) and
represent the average of at least three assays performed in triplicate
and are expressed as mean6SEM. *P,0.001. Statistical analysis was
performed by one-way ANOVA followed by Bonferroni’s post hoc test.
doi:10.1371/journal.pone.0006215.g003
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signaling pathway has also been shown to provide neuroprotection
in stress-induced conditions [34], which is in line with the 6c-
induced protection observed against the oxidative stress caused by
MPP
+. These results are exciting since targeting MAPK signaling
pathways represents an interesting way to slow down neurode-
generation in PD [48].
Quantitative structure–activity relationship (QSAR) studies
[49], allow us to predict the potency of compound 6c to cross
the BBB by passive diffusion. Indeed, comparisons of determining
factors for BBB penetration are given in Table 2. Excluding any
currently unknown pharmacological parameters, the physico-
chemical properties of compound 6c are close to those expected of
an orally available CNS drug, suggesting that compound 6c is a
serious candidate for in vivo studies and therapeutic use.
Furthermore, preliminary toxically studies performed on mice
show that compound 6c does not present any toxic effect in a
chronical treatment (300 mg/kg/day in a 15 days treatment) when
orally administrated (results not shown).
In summary, we have designed and synthesized a class of
quinoline-derived small molecules, some of which show potent
neurotrophic activity, expressed as dual protective and trophic
activities. These compounds are synthetic small molecules derived
from LBA that exhibit potency in the nanomolar range. Lead
compound 6c promotes specific survival and neuritogenesis of DA
neurons, preserving DA transporter activity in two relevant in vitro
models of PD, and does not influence cellular proliferation, thus
representingapotentialcandidatefortherapeuticapplicationsinPD.
Materials and Methods
More details are available in supplementary informations S1, S2, S3, S4,
S5, S6, S7, S8, S9, S10.
Preparation and Spectroscopic Data of Compounds 2a–c-
9a–g
see Supplementary Information - S1.
Primary Mesencephalic Cultures
The embryos were removed at embryonic day 15.5 from
pregnant Sprague-Dawley rats (Elevage Janvier, Le Genest St. Isle,
France) that had been anesthetized, then decerebrated. Ventral
mesencephalon were dissected and collected. Cell suspensions
prepared by mechanical trituration precoated overnight with
1 mg/ml polyethylenimine in borate buffer, pH 8.3. The cells
were then maintained for maturation and differentiation in B27-
supplemented Neurobasal culture medium. Cultures were treated
at DIV1 and every four days 300 mL of culture medium were
replaced by medium supplemented with treatments. For more
details See Supplementary Information - S2.
Figure 4. Protective effect of compound 6c against neurotoxin 1-methyl-4-phenylpyridinium (MPP
+) toxicity. (A) Treatment of MPP
+-
treated mesencephalic cultures with compound 6c resulted in the partial rescue of DA neurons in a dose-dependent manner. Cultures were
maintained from DIV1 to DIV8 in the presence or absence of compound 6c and were treated with MPP
+ for 48 h from DIV5 to DIV7. Neuronal survival
was quantified by counting TH
+ immunolabeled neurons at DIV8. Values are normalized to a toxin-free control and represent the average of three
assays performed in triplicate expressed as mean6SEM. Statistical analysis was performed by one-way ANOVA followed by Dunnett’s post hoc test.
*P,0.001. (B) Compound 6c treatment reduced MPP
+-induced neurite degeneration. Images illustrate untreated (CTL) and treated (MPP
+, 6c)
cultures. Images were acquired with an inverted fluorescent microscope coupled to a digital camera.
doi:10.1371/journal.pone.0006215.g004
Figure 5. Compound 6c-induced neurotrophic effect is inde-
pendent of glial proliferation. Proliferation in mesencephalic
cultures was not affected by compound 6c treatment (d) compared
to non-treated cultures (CTL) (a). EGF at 20 ng/mL (b) and arabinoside-C
(ARA-C) at 2 mM (c), respectively, were used as controls for activation or
inhibition of cell proliferation. [
3H]-thymidine was added to the cultures
for 18 h from DIV7 to DIV8. Proliferation was assessed by counting [
3H]-
thymidine
+ nuclei appearing from autoradiographic emulsion. Images
were acquired with a phase-contrast microscope coupled to a digital
camera. Values are normalized to the non-treated cultures (CTL) and
represent the average of three assays performed in triplicate and
expressed as mean6SEM.
doi:10.1371/journal.pone.0006215.g005
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After 12 min fixation with a 4% formaldehyde solution in
Dulbecco’s phosphate-buffered saline (PBS), cells were washed
three times with PBS and then incubated in PBS
+ (PBS containing
0.2% Triton X-100, 10% fetal bovine serum (Sigma, Saint Louis,
MO) and 0.01% thimerozal (Sigma, Saint Quentin Fallavier,
France) for 1 hour. The cells were further incubated overnight at
4uC with a rabbit anti-TH polyclonal antibody or a mouse anti-
MAP-2 monoclonal antibody. Subsequent incubations were
performed, at room temperature, with a secondary anti-rabbit
IgG cyanin 3 conjugate or an Alexa Fluor 488 F(ab’)2 fragment of
goat anti-rabbit IgG or an anti-mouse IGg cyanin 3 conjugate.
Concerning phospho-ErK1/2 (pp42/pp44) immunofluorescence
staining, the cultures were incubated overnight at 4uC with a
mouse monoclonal anti phospho-ERK1/2 antibody diluted at
1:100 in PBS
+ then washed and incubated with an anti-mouse IGg
cyanin 3 conjugate. For more details See Supplementary Information -
S3.
Neuroprotection was Assessed by TH Immunopositive
(TH
+) Neuron counting
For more details See Supplementary Information - S4.
Neuritogenesis, Quantification
For more details See Supplementary Information - S5.
MPP
+ Intoxication of Mesencephalic Cultures
MPP
+ intoxication was performed according to a method
previously described [19]. For more details See Supplementary
Information – S6.
Uptakes of [7.8-
3H]-DA ([
3H]-DA) and 4-Amino-n-
[2,3-
3H]butyric acid ([
3H]-GABA)
High-affinity uptake of [
3H]-DA and [
3H]-GABA was deter-
mined according to a method previously described [25]. For more
details See Supplementary Information – S7.
Figure 6. Involvement of extracellular signal-regulated kinase (ERK1/2) activation in compound 6c-induced neurotrophic effect. (A)
Addition of PD98059 disrupted the compound 6c-induced neuroprotective effect. Neuronal survival was assessed by counting TH
+ neurons at DIV12
in 100 or 1000 nM compound 6c-treated cultures in the presence or absence of the MEK inhibitor PD98059 at 10 mM. Dbc-AMP at 200 mM was used
as a positive control. Values are normalized to the non-treated control and represent the average of three assays performed in triplicate and
expressed as mean6SEM. Statistical analysis was performed by two-way ANOVA followed by Duncan’s post hoc test. *P,0.05. (B) Addition of
PD98059 reduced the neuritogenic effect of compound 6c. Images were acquired with an inverted fluorescent microscope coupled to a digital
camera. (C) Treatment with compound 6c resulted in an increase of ERK1/2 phosphorylation in a dose-dependent manner. Western blot analyses
were performed at DIV12 with proteic lysates from cultures maintained in the presence of compound 6c. Quantification of protein levels was
performed with Image J software in at least three independent experiments and is expressed as mean6SEM. Statistical analysis was performed by
two-way ANOVA followed by Duncan’s post hoc test. *P,0.05. (D) Visualization of the ERK1/2 phosphorylated forms (Pp44/Pp42) in DA neurons by
dual immunolabeling of TH (green) and Pp44/Pp42 (ERK1/2) (red) [48]. Treatment with compound 6c resulted in an increase of ERK1/2
phosphorylated forms in DA neurons. This effect was disrupted by the addition of PD98059 at 10 mM. Images were acquired with unchanged
exposure using an inverted fluorescent microscope coupled to a digital camera. Merge were performed using image analysis software.
doi:10.1371/journal.pone.0006215.g006
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Mesencephalic treated cultures with 10, 100 or 1000 nM of
compound 6c were exposed to 1 mCi of [methyl-
3H]-thymidine
After
washes, the cells were fixed and positive nuclei were visualized
with emulsion then quantified by counting. For more details See
Supplementary Information – S8.
ERK1/2 Activation
ERK1/2 activation was assessed according to previously
described methods [47]. For more details See Supplementary
Information – S9.
Statistical Analysis
Comparisons between two groups were performed with
Student’s t test. Multiple comparisons against a single reference
group were made by one-way analysis of variance (ANOVA)
followed by Dunnett’s or Bonferroni’s post-hoc tests. When all
pairwise comparisons were made, two-way ANOVA was used
followed by Duncan’s test. S.E.M. values were derived from at
least three values per condition of three independent experiments.
Supporting Information
Supporting Information S1
Found at: doi:10.1371/journal.pone.0006215.s001 (.15 MB PDF)
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